Sort
15,842 grants matching “pancreatic cancer”
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer
$221,727Neeha Zaidi · Johns Hopkins University · K08 · FY2023 · CA
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer
$221,727Neeha Zaidi · Johns Hopkins University · K08 · FY2021 · CA
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer
$221,727Neeha Zaidi · Johns Hopkins University · K08 · FY2024 · CA
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer
$221,727Neeha Zaidi · Johns Hopkins University · K08 · FY2022 · CA
Administrative Core
$221,697Dean E. Brenner · University Of Michigan At Ann Arbor · P50 · FY2011 · CA
Core B: Human Pancreas
$221,680Walter Gwang-Up Park · Stanford University · P01 · FY2022 · CA
Core B: Human Pancreas
$221,679Walter Gwang-Up Park · Stanford University · P01 · FY2023 · CA
Clinical Photodynamic Therapy for Pancreatic and Biliary Tract Cancer
$221,670Stephen Pereira · Massachusetts General Hospital · P01 · FY2009 · CA
Examining cell signaling activity during cell migration via fluorescence lifetime biosensors in Glioblastoma and Pancreatic Ductal Adenocarcinoma
$221,640David J Odde · University Of Minnesota · U54 · FY2019 · CA
Examining cell signaling activity during cell migration via fluorescence lifetime biosensors in Glioblastoma and Pancreatic Ductal Adenocarcinoma
$221,640David J Odde · University Of Minnesota · U54 · FY2019 · CA
An inhibitor of multiple anti-apoptotic gene products for pancreatic cancer
$221,589Fengzhi Li · Roswell Park Cancer Institute Corp · R21 · FY2014 · CA
Metabolic regulation of FOLFIRINOX acquired resistance in pancreatic cancer
$221,403Pankaj Kumar Singh · University Of Oklahoma Hlth Sciences Ctr · U54 · FY2025 · CA
Operationalizing DNMT1-Targeting to Treat Chemorefractory Pancreatic Cancer
$221,286Yogen Saunthararajah · Cleveland Clinic Lerner Com-Cwru · R21 · FY2023 · CA
Development of Novel Informative Preclinical Animal Models - CAPR Infrastructure
$221,242Shyam Sharan · Division Of Basic Sciences - Nci · ZIG · FY2020 · CA
Preclinical Modelling and Therapeutic Development for Other Cancer Indications
$221,242Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Physiologic Roles of Activin and Myostatin Antagonists
$221,240Alan L Schneyer · University Of Massachusetts Amherst · R01 · FY2009 · DK
NUR77 Agonists: New Targets for Pancreatic Cancer Chemotherapy
$221,160Stephen H Safe · Texas A&M University Health Science Ctr · R01 · FY2009 · CA
NUR77 Agonists: New Targets for Pancreatic Cancer Chemotherapy
$221,160Stephen H Safe · Texas A&M University Health Science Ctr · R01 · FY2010 · CA
The Role of AGR2 in a Murine Model of Pancreatic Adenocarcinoma
$221,153Anson W Lowe · Stanford University · R21 · FY2012 · CA
Immuno-vasculogenic hydrogels for islet engraftment and localized tolerance
$221,123Haval Shirwan · University Of Louisville · R21 · FY2016 · EB
TSNA AND PANCREATIC CANCER
$221,113Institute For Cancer Prevention · R01 · FY2000 · CA
Exploring the interaction of lipid metabolism with the hexosamine pathway and tumor growth
$220,894Ioanna Papandreou · Ohio State University · R21 · FY2024 · CA
Pathophysiology, Epidemiology, and Prevention of Pancreatogenic Diabetes - Administrative Supplement
$220,763Stephen J Pandol · Cedars-Sinai Medical Center · U01 · FY2019 · DK
Validation of Amplified Genes in Pancreatic Cancer
$220,673Jeffrey M. Trent · Translational Genomics Research Inst · P01 · FY2009 · CA
Development of a STAT2 knock-out hamster model for wild-type filovirus infections
$220,647Zhongde Wang · Auratus Bio, Llc · R41 · FY2016 · OD